Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 206 | 2024 | 447 | 34.590 |
Why?
|
Neoplasms, Glandular and Epithelial | 30 | 2018 | 42 | 6.870 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 51 | 2023 | 989 | 6.160 |
Why?
|
Immunoconjugates | 14 | 2022 | 38 | 5.800 |
Why?
|
Cystadenocarcinoma, Serous | 42 | 2024 | 70 | 5.730 |
Why?
|
Neoplasm Recurrence, Local | 33 | 2024 | 614 | 5.730 |
Why?
|
Endometrial Neoplasms | 28 | 2023 | 138 | 5.530 |
Why?
|
Antibodies, Monoclonal, Humanized | 21 | 2023 | 225 | 4.210 |
Why?
|
Maytansine | 9 | 2021 | 9 | 4.080 |
Why?
|
Antineoplastic Agents | 31 | 2023 | 1171 | 3.930 |
Why?
|
Gene Expression Profiling | 51 | 2021 | 1032 | 3.700 |
Why?
|
Female | 279 | 2024 | 26472 | 3.630 |
Why?
|
Gene Expression Regulation, Neoplastic | 80 | 2021 | 828 | 3.550 |
Why?
|
Uterine Cervical Neoplasms | 18 | 2024 | 277 | 3.370 |
Why?
|
Proto-Oncogene Proteins c-jun | 49 | 2011 | 75 | 3.250 |
Why?
|
Drug Resistance, Neoplasm | 24 | 2024 | 308 | 3.160 |
Why?
|
Humans | 365 | 2024 | 49974 | 2.910 |
Why?
|
Peritoneal Neoplasms | 10 | 2021 | 59 | 2.520 |
Why?
|
Transcription Factor AP-1 | 29 | 2013 | 63 | 2.520 |
Why?
|
Molecular Targeted Therapy | 12 | 2021 | 119 | 2.240 |
Why?
|
Folate Receptor 1 | 7 | 2020 | 24 | 2.210 |
Why?
|
Aged | 102 | 2024 | 9310 | 2.190 |
Why?
|
Paclitaxel | 25 | 2023 | 84 | 2.090 |
Why?
|
Fallopian Tube Neoplasms | 6 | 2018 | 14 | 2.030 |
Why?
|
Middle Aged | 111 | 2024 | 12069 | 2.000 |
Why?
|
Adenocarcinoma, Clear Cell | 14 | 2019 | 34 | 1.960 |
Why?
|
Prognosis | 46 | 2021 | 1942 | 1.920 |
Why?
|
Neoplasm Staging | 43 | 2021 | 740 | 1.830 |
Why?
|
Carboplatin | 22 | 2023 | 53 | 1.730 |
Why?
|
Oligonucleotide Array Sequence Analysis | 30 | 2016 | 411 | 1.730 |
Why?
|
Signal Transduction | 42 | 2019 | 1618 | 1.650 |
Why?
|
Uterine Neoplasms | 8 | 2016 | 60 | 1.640 |
Why?
|
Carcinoma, Endometrioid | 12 | 2019 | 38 | 1.640 |
Why?
|
Neoplasms | 13 | 2023 | 1235 | 1.610 |
Why?
|
Mutation | 36 | 2019 | 1294 | 1.600 |
Why?
|
Carcinoma | 12 | 2012 | 138 | 1.540 |
Why?
|
Piperazines | 7 | 2019 | 117 | 1.490 |
Why?
|
Genital Neoplasms, Female | 7 | 2016 | 41 | 1.480 |
Why?
|
Adult | 79 | 2024 | 13236 | 1.430 |
Why?
|
Transcriptome | 11 | 2019 | 315 | 1.390 |
Why?
|
Cell Line, Tumor | 50 | 2021 | 1403 | 1.380 |
Why?
|
Neoplasm Proteins | 13 | 2017 | 322 | 1.380 |
Why?
|
Disease-Free Survival | 23 | 2023 | 454 | 1.370 |
Why?
|
Aged, 80 and over | 46 | 2023 | 3129 | 1.350 |
Why?
|
Clinical Trials as Topic | 11 | 2020 | 461 | 1.340 |
Why?
|
Carcinoma, Papillary | 5 | 2012 | 48 | 1.290 |
Why?
|
Breast Neoplasms | 16 | 2022 | 1174 | 1.290 |
Why?
|
Phthalazines | 6 | 2019 | 20 | 1.250 |
Why?
|
Immunohistochemistry | 36 | 2022 | 973 | 1.250 |
Why?
|
Genomics | 6 | 2021 | 286 | 1.220 |
Why?
|
Genetic Predisposition to Disease | 14 | 2017 | 510 | 1.190 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2020 | 74 | 1.160 |
Why?
|
Recombinant Fusion Proteins | 10 | 2024 | 181 | 1.160 |
Why?
|
Cell Transformation, Neoplastic | 19 | 2011 | 177 | 1.120 |
Why?
|
Databases, Genetic | 7 | 2021 | 88 | 1.110 |
Why?
|
Animals | 96 | 2024 | 13187 | 1.110 |
Why?
|
Carcinosarcoma | 6 | 2016 | 18 | 1.100 |
Why?
|
Lung Neoplasms | 29 | 2017 | 606 | 1.080 |
Why?
|
Platinum | 4 | 2022 | 11 | 1.040 |
Why?
|
Mice | 65 | 2024 | 5739 | 1.010 |
Why?
|
Transcription Factors | 22 | 2018 | 561 | 1.000 |
Why?
|
Cell Cycle Proteins | 13 | 2012 | 166 | 0.990 |
Why?
|
Phosphatidylinositol 3-Kinases | 9 | 2019 | 141 | 0.970 |
Why?
|
Apoptosis | 30 | 2021 | 1101 | 0.970 |
Why?
|
RNA, Messenger | 36 | 2015 | 1105 | 0.950 |
Why?
|
Cisplatin | 16 | 2023 | 278 | 0.930 |
Why?
|
DNA, Neoplasm | 18 | 2017 | 147 | 0.910 |
Why?
|
Tumor Suppressor Protein p53 | 12 | 2016 | 202 | 0.890 |
Why?
|
Proto-Oncogene Proteins c-akt | 9 | 2024 | 157 | 0.890 |
Why?
|
Genes, jun | 17 | 2007 | 21 | 0.870 |
Why?
|
Germ-Line Mutation | 5 | 2019 | 61 | 0.860 |
Why?
|
Cell Movement | 17 | 2021 | 247 | 0.850 |
Why?
|
Adenocarcinoma, Mucinous | 8 | 2014 | 19 | 0.840 |
Why?
|
Neoplasm Invasiveness | 19 | 2016 | 267 | 0.840 |
Why?
|
Neutropenia | 1 | 2023 | 116 | 0.830 |
Why?
|
Niacinamide | 3 | 2019 | 22 | 0.820 |
Why?
|
Pyridines | 2 | 2015 | 130 | 0.810 |
Why?
|
Nuclear Proteins | 11 | 2018 | 242 | 0.810 |
Why?
|
Optical Imaging | 2 | 2019 | 25 | 0.790 |
Why?
|
DNA-Binding Proteins | 19 | 2018 | 427 | 0.780 |
Why?
|
Proto-Oncogene Proteins | 14 | 2012 | 149 | 0.780 |
Why?
|
Contrast Media | 3 | 2019 | 184 | 0.770 |
Why?
|
Neoplasm Grading | 15 | 2021 | 123 | 0.760 |
Why?
|
Nanotubes, Carbon | 2 | 2019 | 66 | 0.750 |
Why?
|
Phosphoprotein Phosphatases | 2 | 2016 | 17 | 0.750 |
Why?
|
Treatment Outcome | 27 | 2023 | 5141 | 0.750 |
Why?
|
Genes, Tumor Suppressor | 15 | 2015 | 73 | 0.740 |
Why?
|
Oncogenes | 16 | 2013 | 57 | 0.730 |
Why?
|
Tumor Cells, Cultured | 39 | 2021 | 465 | 0.730 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2017 | 549 | 0.720 |
Why?
|
Survival Rate | 19 | 2020 | 894 | 0.710 |
Why?
|
Genes, ras | 11 | 2001 | 43 | 0.700 |
Why?
|
Tumor Microenvironment | 8 | 2024 | 212 | 0.690 |
Why?
|
Tumor Suppressor Proteins | 9 | 2016 | 128 | 0.690 |
Why?
|
Gene Amplification | 14 | 2013 | 57 | 0.690 |
Why?
|
Mitogen-Activated Protein Kinases | 17 | 2009 | 155 | 0.690 |
Why?
|
Quality of Life | 3 | 2023 | 836 | 0.670 |
Why?
|
Ovary | 9 | 2019 | 104 | 0.670 |
Why?
|
Disease Progression | 16 | 2022 | 825 | 0.670 |
Why?
|
Transfection | 31 | 2020 | 354 | 0.660 |
Why?
|
ras Proteins | 9 | 2012 | 64 | 0.660 |
Why?
|
Paraffin Embedding | 6 | 2020 | 53 | 0.660 |
Why?
|
Adenocarcinoma | 10 | 2021 | 396 | 0.650 |
Why?
|
Tablets | 2 | 2018 | 31 | 0.650 |
Why?
|
Contractile Proteins | 3 | 2019 | 5 | 0.650 |
Why?
|
Antibodies, Monoclonal | 8 | 2023 | 459 | 0.640 |
Why?
|
Kaplan-Meier Estimate | 12 | 2020 | 466 | 0.640 |
Why?
|
Transforming Growth Factor beta | 5 | 2020 | 144 | 0.640 |
Why?
|
Proteomics | 3 | 2024 | 329 | 0.630 |
Why?
|
Cell Proliferation | 26 | 2021 | 1007 | 0.630 |
Why?
|
Polymorphism, Single Nucleotide | 15 | 2019 | 485 | 0.630 |
Why?
|
Cell Cycle | 13 | 2012 | 231 | 0.630 |
Why?
|
Gene Expression | 20 | 2016 | 609 | 0.620 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2015 | 95 | 0.610 |
Why?
|
NF-kappa B | 9 | 2013 | 314 | 0.600 |
Why?
|
Gene Expression Regulation | 19 | 2014 | 976 | 0.600 |
Why?
|
Up-Regulation | 15 | 2017 | 452 | 0.600 |
Why?
|
Glycoproteins | 3 | 2017 | 115 | 0.600 |
Why?
|
Transcription, Genetic | 19 | 2009 | 369 | 0.590 |
Why?
|
Ascitic Fluid | 1 | 2017 | 12 | 0.590 |
Why?
|
Transcriptional Activation | 14 | 2009 | 121 | 0.590 |
Why?
|
Proportional Hazards Models | 9 | 2021 | 402 | 0.590 |
Why?
|
Xenograft Model Antitumor Assays | 8 | 2017 | 211 | 0.590 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 22 | 2015 | 595 | 0.580 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2015 | 142 | 0.580 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2010 | 36 | 0.580 |
Why?
|
BRCA1 Protein | 8 | 2019 | 31 | 0.580 |
Why?
|
MicroRNAs | 9 | 2017 | 353 | 0.570 |
Why?
|
Clone Cells | 4 | 2016 | 74 | 0.570 |
Why?
|
Survival Analysis | 17 | 2023 | 653 | 0.560 |
Why?
|
Neoplastic Stem Cells | 4 | 2018 | 103 | 0.560 |
Why?
|
Protein Kinase Inhibitors | 8 | 2019 | 204 | 0.560 |
Why?
|
Promoter Regions, Genetic | 16 | 2013 | 475 | 0.560 |
Why?
|
Tissue Fixation | 2 | 2020 | 36 | 0.550 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 7 | 2011 | 18 | 0.540 |
Why?
|
Proto-Oncogene Proteins c-fos | 16 | 2009 | 61 | 0.540 |
Why?
|
Mice, Nude | 14 | 2019 | 252 | 0.530 |
Why?
|
Epithelial Cells | 10 | 2013 | 209 | 0.530 |
Why?
|
Oxazines | 1 | 2015 | 3 | 0.520 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2016 | 43 | 0.520 |
Why?
|
Acid Anhydride Hydrolases | 3 | 2001 | 15 | 0.520 |
Why?
|
Cluster Analysis | 9 | 2015 | 235 | 0.520 |
Why?
|
Young Adult | 13 | 2024 | 3958 | 0.510 |
Why?
|
Microtubules | 1 | 2015 | 41 | 0.510 |
Why?
|
Genome-Wide Association Study | 7 | 2017 | 166 | 0.500 |
Why?
|
Formaldehyde | 1 | 2015 | 52 | 0.500 |
Why?
|
Polymerase Chain Reaction | 12 | 2012 | 453 | 0.500 |
Why?
|
Diarrhea | 5 | 2019 | 92 | 0.500 |
Why?
|
Nanotechnology | 1 | 2015 | 35 | 0.490 |
Why?
|
Intercellular Signaling Peptides and Proteins | 4 | 2023 | 104 | 0.490 |
Why?
|
Fatigue | 5 | 2019 | 117 | 0.490 |
Why?
|
Precancerous Conditions | 5 | 2009 | 83 | 0.490 |
Why?
|
Quinoxalines | 3 | 2021 | 27 | 0.490 |
Why?
|
Prostatic Neoplasms | 4 | 2015 | 394 | 0.490 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 169 | 0.480 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2015 | 244 | 0.470 |
Why?
|
Predictive Value of Tests | 9 | 2014 | 903 | 0.470 |
Why?
|
Piperidines | 3 | 2019 | 98 | 0.460 |
Why?
|
Neoplasm Metastasis | 7 | 2024 | 231 | 0.460 |
Why?
|
Nausea | 4 | 2018 | 50 | 0.460 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 5 | 2019 | 18 | 0.460 |
Why?
|
Platinum Compounds | 5 | 2019 | 10 | 0.460 |
Why?
|
Microdissection | 3 | 2019 | 19 | 0.450 |
Why?
|
Blotting, Western | 16 | 2017 | 601 | 0.450 |
Why?
|
Sarcoma | 1 | 2014 | 67 | 0.440 |
Why?
|
Proteome | 1 | 2015 | 173 | 0.440 |
Why?
|
Fibroblast Growth Factors | 1 | 2013 | 47 | 0.440 |
Why?
|
Pyrimidines | 2 | 2016 | 192 | 0.440 |
Why?
|
Antigens, CD | 3 | 2010 | 219 | 0.440 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 8 | 2017 | 154 | 0.440 |
Why?
|
Angioplasty, Balloon | 4 | 2002 | 65 | 0.440 |
Why?
|
Phosphoproteins | 7 | 2021 | 107 | 0.440 |
Why?
|
Chromosomes, Human, Pair 8 | 2 | 2010 | 14 | 0.440 |
Why?
|
Angiogenesis Inhibitors | 6 | 2023 | 187 | 0.440 |
Why?
|
Rats | 23 | 2013 | 3305 | 0.440 |
Why?
|
Drug Administration Schedule | 13 | 2020 | 376 | 0.430 |
Why?
|
Genome, Human | 7 | 2019 | 111 | 0.420 |
Why?
|
Microtubule-Associated Proteins | 4 | 2001 | 67 | 0.420 |
Why?
|
Genes, erbB-2 | 2 | 2009 | 8 | 0.420 |
Why?
|
Cell Division | 17 | 2004 | 292 | 0.420 |
Why?
|
Genes, myc | 4 | 2009 | 40 | 0.410 |
Why?
|
beta Karyopherins | 3 | 2021 | 4 | 0.410 |
Why?
|
Stromal Cells | 6 | 2019 | 72 | 0.410 |
Why?
|
Base Sequence | 22 | 2010 | 643 | 0.410 |
Why?
|
In Situ Hybridization, Fluorescence | 6 | 2022 | 259 | 0.400 |
Why?
|
RNA, Small Interfering | 15 | 2017 | 215 | 0.400 |
Why?
|
Dose-Response Relationship, Drug | 10 | 2020 | 1376 | 0.400 |
Why?
|
Drug Delivery Systems | 2 | 2014 | 138 | 0.400 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 4 | 2018 | 7 | 0.390 |
Why?
|
Follow-Up Studies | 11 | 2019 | 2182 | 0.390 |
Why?
|
Cell Adhesion | 8 | 2015 | 158 | 0.390 |
Why?
|
Pancreatic Neoplasms | 3 | 2019 | 208 | 0.390 |
Why?
|
Thrombocytopenia | 3 | 2022 | 85 | 0.390 |
Why?
|
Cell Differentiation | 10 | 2004 | 651 | 0.390 |
Why?
|
Maximum Tolerated Dose | 4 | 2019 | 37 | 0.380 |
Why?
|
Benzenesulfonates | 1 | 2010 | 10 | 0.380 |
Why?
|
Genes, p53 | 5 | 2001 | 51 | 0.380 |
Why?
|
Leiomyosarcoma | 2 | 2003 | 23 | 0.370 |
Why?
|
Cystadenoma, Serous | 2 | 2016 | 5 | 0.370 |
Why?
|
Pyrroles | 3 | 2021 | 69 | 0.370 |
Why?
|
ADP-ribosyl Cyclase | 1 | 2010 | 5 | 0.370 |
Why?
|
Medical Oncology | 2 | 2019 | 94 | 0.370 |
Why?
|
Morpholines | 5 | 2018 | 71 | 0.360 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 16 | 2010 | 72 | 0.360 |
Why?
|
Tissue Array Analysis | 8 | 2016 | 45 | 0.360 |
Why?
|
Research | 2 | 2008 | 110 | 0.360 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2010 | 20 | 0.360 |
Why?
|
Recombinational DNA Repair | 2 | 2021 | 9 | 0.360 |
Why?
|
Nucleic Acid Hybridization | 2 | 2007 | 54 | 0.350 |
Why?
|
DNA Mutational Analysis | 9 | 2016 | 175 | 0.350 |
Why?
|
Fibroblasts | 8 | 2013 | 345 | 0.340 |
Why?
|
Proteins | 4 | 2023 | 342 | 0.340 |
Why?
|
Cell Line | 20 | 2013 | 1000 | 0.340 |
Why?
|
Indazoles | 2 | 2019 | 47 | 0.330 |
Why?
|
Doxorubicin | 5 | 2019 | 233 | 0.330 |
Why?
|
Genome | 2 | 2006 | 65 | 0.330 |
Why?
|
Molecular Sequence Data | 20 | 2007 | 792 | 0.330 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 10 | 2012 | 33 | 0.330 |
Why?
|
Prospective Studies | 11 | 2021 | 2364 | 0.330 |
Why?
|
Double-Blind Method | 6 | 2021 | 681 | 0.320 |
Why?
|
Genes, fos | 13 | 2007 | 28 | 0.320 |
Why?
|
RNA, Neoplasm | 9 | 2015 | 44 | 0.320 |
Why?
|
Camptothecin | 2 | 2021 | 16 | 0.320 |
Why?
|
Cyclodextrins | 2 | 2021 | 17 | 0.320 |
Why?
|
Receptor Protein-Tyrosine Kinases | 3 | 2009 | 51 | 0.310 |
Why?
|
Chemotherapy, Adjuvant | 7 | 2019 | 119 | 0.310 |
Why?
|
Osteosarcoma | 1 | 2008 | 47 | 0.310 |
Why?
|
RNA Interference | 6 | 2017 | 179 | 0.310 |
Why?
|
Nanoparticles | 4 | 2017 | 145 | 0.310 |
Why?
|
Models, Biological | 6 | 2012 | 727 | 0.300 |
Why?
|
Topotecan | 3 | 2023 | 17 | 0.300 |
Why?
|
Benzimidazoles | 2 | 2021 | 48 | 0.300 |
Why?
|
Fibroblast Growth Factor 1 | 1 | 2007 | 1 | 0.300 |
Why?
|
Tumor Burden | 5 | 2015 | 132 | 0.300 |
Why?
|
Bacteriophage M13 | 2 | 2019 | 2 | 0.290 |
Why?
|
Societies, Medical | 1 | 2008 | 175 | 0.290 |
Why?
|
Reproducibility of Results | 7 | 2018 | 1193 | 0.290 |
Why?
|
Disease Models, Animal | 6 | 2024 | 1455 | 0.290 |
Why?
|
Pilot Projects | 2 | 2022 | 699 | 0.290 |
Why?
|
Maintenance Chemotherapy | 4 | 2021 | 49 | 0.290 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2004 | 318 | 0.290 |
Why?
|
BRCA2 Protein | 5 | 2019 | 15 | 0.280 |
Why?
|
Bone Neoplasms | 1 | 2008 | 179 | 0.280 |
Why?
|
Vision Disorders | 2 | 2017 | 57 | 0.280 |
Why?
|
Cyclin A | 2 | 2008 | 6 | 0.280 |
Why?
|
Binding Sites | 11 | 2013 | 374 | 0.270 |
Why?
|
Sulfonamides | 2 | 2019 | 129 | 0.270 |
Why?
|
Proto-Oncogenes | 8 | 2003 | 27 | 0.270 |
Why?
|
Receptors, Estrogen | 6 | 2013 | 130 | 0.260 |
Why?
|
Tumor Necrosis Factor-alpha | 8 | 2020 | 388 | 0.260 |
Why?
|
Membrane Proteins | 5 | 2019 | 341 | 0.260 |
Why?
|
Mice, SCID | 5 | 2021 | 175 | 0.260 |
Why?
|
Genes, Dominant | 6 | 2005 | 19 | 0.260 |
Why?
|
MAP Kinase Kinase Kinases | 3 | 2019 | 19 | 0.260 |
Why?
|
ras-GRF1 | 1 | 2005 | 1 | 0.260 |
Why?
|
Recurrence | 5 | 2023 | 652 | 0.260 |
Why?
|
CA-125 Antigen | 6 | 2021 | 17 | 0.260 |
Why?
|
Adaptor Proteins, Signal Transducing | 4 | 2014 | 197 | 0.250 |
Why?
|
DNA | 12 | 2008 | 541 | 0.250 |
Why?
|
Genetic Loci | 2 | 2017 | 49 | 0.250 |
Why?
|
Cells, Cultured | 15 | 2009 | 1573 | 0.250 |
Why?
|
Protein Biosynthesis | 3 | 2001 | 253 | 0.250 |
Why?
|
Blotting, Northern | 9 | 2010 | 109 | 0.250 |
Why?
|
Microvessels | 3 | 2017 | 29 | 0.250 |
Why?
|
Tetradecanoylphorbol Acetate | 8 | 1996 | 46 | 0.250 |
Why?
|
Renal Artery Obstruction | 2 | 2002 | 21 | 0.250 |
Why?
|
DNA Copy Number Variations | 2 | 2017 | 110 | 0.240 |
Why?
|
Interleukin-6 | 2 | 2020 | 264 | 0.240 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2023 | 201 | 0.240 |
Why?
|
HMGA1a Protein | 1 | 2004 | 1 | 0.240 |
Why?
|
Mutation Rate | 2 | 2016 | 36 | 0.240 |
Why?
|
Neutrophil Activation | 1 | 2024 | 14 | 0.240 |
Why?
|
Iliac Artery | 2 | 2001 | 33 | 0.240 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 6 | 1999 | 33 | 0.240 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 7 | 2011 | 67 | 0.230 |
Why?
|
Benzamides | 2 | 2017 | 51 | 0.230 |
Why?
|
Cyclin D1 | 2 | 2002 | 56 | 0.230 |
Why?
|
Organoplatinum Compounds | 3 | 2020 | 14 | 0.230 |
Why?
|
Biological Therapy | 1 | 2003 | 16 | 0.230 |
Why?
|
Stents | 3 | 2002 | 338 | 0.230 |
Why?
|
Cell Lineage | 2 | 2018 | 83 | 0.230 |
Why?
|
Point Mutation | 7 | 2012 | 65 | 0.230 |
Why?
|
United States | 12 | 2020 | 4860 | 0.230 |
Why?
|
Luciferases | 5 | 2019 | 50 | 0.230 |
Why?
|
Microtubule Proteins | 1 | 2003 | 3 | 0.220 |
Why?
|
Cohort Studies | 6 | 2019 | 1422 | 0.220 |
Why?
|
Neoplasm Transplantation | 6 | 2013 | 85 | 0.220 |
Why?
|
Receptor, erbB-2 | 2 | 2022 | 73 | 0.220 |
Why?
|
Quinazolines | 3 | 2019 | 33 | 0.220 |
Why?
|
Down-Regulation | 10 | 2011 | 348 | 0.220 |
Why?
|
Epithelium | 5 | 2011 | 65 | 0.220 |
Why?
|
Drug Synergism | 3 | 2021 | 150 | 0.220 |
Why?
|
Neutrophils | 1 | 2024 | 145 | 0.220 |
Why?
|
Fenretinide | 2 | 2004 | 5 | 0.220 |
Why?
|
Histone Deacetylases | 1 | 2003 | 50 | 0.220 |
Why?
|
Genes, Reporter | 6 | 2006 | 89 | 0.220 |
Why?
|
Protein Binding | 10 | 2016 | 660 | 0.210 |
Why?
|
Cell Nucleus | 6 | 2016 | 183 | 0.210 |
Why?
|
Proto-Oncogene Proteins c-myc | 7 | 1996 | 50 | 0.210 |
Why?
|
Molecular Biology | 4 | 2016 | 25 | 0.210 |
Why?
|
Tamoxifen | 4 | 2016 | 60 | 0.210 |
Why?
|
Adenocarcinoma, Papillary | 1 | 2002 | 5 | 0.210 |
Why?
|
Protein Processing, Post-Translational | 2 | 2003 | 171 | 0.210 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 2002 | 24 | 0.210 |
Why?
|
Apoptosis Regulatory Proteins | 5 | 2023 | 86 | 0.210 |
Why?
|
DNA Primers | 7 | 2010 | 207 | 0.210 |
Why?
|
Immediate-Early Proteins | 1 | 2002 | 19 | 0.210 |
Why?
|
Cell Survival | 7 | 2016 | 600 | 0.210 |
Why?
|
Fibromuscular Dysplasia | 1 | 2002 | 2 | 0.210 |
Why?
|
Mycobacterium tuberculosis | 1 | 2024 | 285 | 0.210 |
Why?
|
Fear | 1 | 2023 | 82 | 0.210 |
Why?
|
Versicans | 2 | 2013 | 10 | 0.200 |
Why?
|
Stathmin | 2 | 2017 | 2 | 0.200 |
Why?
|
Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2021 | 1 | 0.200 |
Why?
|
Carnitine O-Palmitoyltransferase | 1 | 2021 | 7 | 0.200 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2019 | 77 | 0.200 |
Why?
|
MAP Kinase Signaling System | 5 | 2013 | 119 | 0.200 |
Why?
|
Cytokines | 3 | 2013 | 612 | 0.200 |
Why?
|
Male | 24 | 2018 | 25241 | 0.200 |
Why?
|
GTP-Binding Proteins | 2 | 1999 | 90 | 0.200 |
Why?
|
Monitoring, Immunologic | 2 | 2011 | 4 | 0.200 |
Why?
|
Disease Management | 2 | 2020 | 174 | 0.200 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 13 | 0.200 |
Why?
|
X Chromosome | 1 | 2001 | 13 | 0.200 |
Why?
|
Cell Death | 4 | 2011 | 181 | 0.200 |
Why?
|
Peptides | 6 | 2017 | 223 | 0.200 |
Why?
|
Epigenesis, Genetic | 2 | 2019 | 374 | 0.200 |
Why?
|
Fibrosis | 2 | 2019 | 179 | 0.200 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2021 | 19 | 0.200 |
Why?
|
Carcinoma, Renal Cell | 2 | 2017 | 105 | 0.190 |
Why?
|
Intermittent Claudication | 1 | 2001 | 12 | 0.190 |
Why?
|
Diabetic Angiopathies | 1 | 2001 | 18 | 0.190 |
Why?
|
Genotype | 8 | 2017 | 537 | 0.190 |
Why?
|
Drug Design | 3 | 2014 | 120 | 0.190 |
Why?
|
Neovascularization, Pathologic | 5 | 2017 | 161 | 0.190 |
Why?
|
Intra-Abdominal Fat | 1 | 2021 | 20 | 0.190 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2021 | 34 | 0.190 |
Why?
|
Subcutaneous Fat | 1 | 2021 | 18 | 0.190 |
Why?
|
Somatomedins | 1 | 2021 | 32 | 0.190 |
Why?
|
Immunotherapy | 2 | 2020 | 238 | 0.190 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2011 | 56 | 0.190 |
Why?
|
MAP Kinase Kinase 1 | 2 | 2019 | 23 | 0.190 |
Why?
|
Gonadal Steroid Hormones | 1 | 2021 | 42 | 0.190 |
Why?
|
Iliac Aneurysm | 1 | 2000 | 10 | 0.190 |
Why?
|
Mechanotransduction, Cellular | 1 | 2021 | 36 | 0.190 |
Why?
|
Kidney Neoplasms | 2 | 2017 | 177 | 0.190 |
Why?
|
Macrophages | 4 | 2000 | 363 | 0.180 |
Why?
|
Ascites | 3 | 2017 | 28 | 0.180 |
Why?
|
National Cancer Institute (U.S.) | 4 | 2020 | 32 | 0.180 |
Why?
|
Survivors | 1 | 2021 | 126 | 0.180 |
Why?
|
CTLA-4 Antigen | 1 | 2020 | 25 | 0.180 |
Why?
|
Cystadenocarcinoma, Papillary | 1 | 2000 | 14 | 0.180 |
Why?
|
Lymphatic Metastasis | 2 | 2019 | 224 | 0.180 |
Why?
|
Genes, BRCA1 | 3 | 2021 | 19 | 0.180 |
Why?
|
Histological Techniques | 1 | 2020 | 8 | 0.180 |
Why?
|
Time Factors | 7 | 2019 | 2903 | 0.180 |
Why?
|
Receptors, Retinoic Acid | 3 | 2004 | 23 | 0.180 |
Why?
|
MAP Kinase Kinase 2 | 1 | 2019 | 6 | 0.180 |
Why?
|
Flow Cytometry | 3 | 2019 | 476 | 0.180 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2019 | 4 | 0.180 |
Why?
|
Retreatment | 2 | 2016 | 57 | 0.180 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2010 | 43 | 0.180 |
Why?
|
Cytoskeletal Proteins | 2 | 2017 | 49 | 0.180 |
Why?
|
Pyridones | 2 | 2019 | 34 | 0.180 |
Why?
|
Peptide Fragments | 7 | 2011 | 215 | 0.180 |
Why?
|
Specimen Handling | 1 | 2020 | 55 | 0.170 |
Why?
|
p21-Activated Kinases | 2 | 2013 | 3 | 0.170 |
Why?
|
Papillomavirus Infections | 1 | 2021 | 155 | 0.170 |
Why?
|
Case-Control Studies | 8 | 2019 | 1131 | 0.170 |
Why?
|
Sensitivity and Specificity | 5 | 2015 | 861 | 0.170 |
Why?
|
Indoles | 3 | 2011 | 278 | 0.170 |
Why?
|
Osteonectin | 1 | 2019 | 10 | 0.170 |
Why?
|
Genetic Markers | 4 | 2012 | 102 | 0.170 |
Why?
|
Doxycycline | 4 | 2013 | 32 | 0.170 |
Why?
|
Retinoblastoma Protein | 6 | 2002 | 19 | 0.170 |
Why?
|
NM23 Nucleoside Diphosphate Kinases | 1 | 2019 | 4 | 0.170 |
Why?
|
U937 Cells | 2 | 2000 | 14 | 0.170 |
Why?
|
Carrier Proteins | 5 | 2012 | 304 | 0.170 |
Why?
|
LIM Domain Proteins | 2 | 2017 | 7 | 0.170 |
Why?
|
MAP Kinase Kinase 4 | 5 | 2004 | 29 | 0.160 |
Why?
|
Thiazoles | 1 | 2019 | 52 | 0.160 |
Why?
|
Early Growth Response Protein 1 | 2 | 2009 | 35 | 0.160 |
Why?
|
Germ Cells | 1 | 2018 | 12 | 0.160 |
Why?
|
Drug Screening Assays, Antitumor | 3 | 2017 | 136 | 0.160 |
Why?
|
Corneal Diseases | 1 | 2018 | 12 | 0.160 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2016 | 52 | 0.160 |
Why?
|
Insulin | 1 | 2021 | 457 | 0.160 |
Why?
|
Surgery, Computer-Assisted | 1 | 2019 | 55 | 0.160 |
Why?
|
Monomeric GTP-Binding Proteins | 2 | 2009 | 9 | 0.160 |
Why?
|
Reactive Oxygen Species | 3 | 2021 | 408 | 0.160 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2018 | 35 | 0.160 |
Why?
|
Green Fluorescent Proteins | 3 | 2019 | 90 | 0.160 |
Why?
|
Angiopoietin-2 | 1 | 2018 | 15 | 0.160 |
Why?
|
Gene Dosage | 3 | 2011 | 78 | 0.160 |
Why?
|
Bufanolides | 1 | 1998 | 1 | 0.160 |
Why?
|
3T3 Cells | 8 | 2000 | 56 | 0.160 |
Why?
|
Microarray Analysis | 2 | 2016 | 73 | 0.160 |
Why?
|
Hospital Costs | 1 | 2018 | 71 | 0.160 |
Why?
|
Phosphorylation | 11 | 2017 | 535 | 0.160 |
Why?
|
Genes, BRCA2 | 2 | 2021 | 12 | 0.160 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 3 | 2024 | 78 | 0.160 |
Why?
|
Risk Factors | 10 | 2017 | 3613 | 0.160 |
Why?
|
Cyclins | 6 | 2001 | 38 | 0.150 |
Why?
|
Muscle, Smooth, Vascular | 1 | 1999 | 130 | 0.150 |
Why?
|
DNA Mismatch Repair | 1 | 2018 | 17 | 0.150 |
Why?
|
Forkhead Transcription Factors | 3 | 2013 | 112 | 0.150 |
Why?
|
Mitosis | 3 | 2012 | 91 | 0.150 |
Why?
|
Incidence | 2 | 2018 | 1003 | 0.150 |
Why?
|
Receptor, Notch2 | 1 | 2017 | 3 | 0.150 |
Why?
|
Enzyme Activation | 11 | 2008 | 276 | 0.150 |
Why?
|
Cell Line, Transformed | 5 | 2013 | 72 | 0.150 |
Why?
|
Polycomb Repressive Complex 2 | 3 | 2012 | 47 | 0.150 |
Why?
|
Homeodomain Proteins | 2 | 2015 | 80 | 0.150 |
Why?
|
Chromatin Immunoprecipitation | 5 | 2011 | 49 | 0.150 |
Why?
|
Data Mining | 2 | 2018 | 39 | 0.150 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2018 | 78 | 0.150 |
Why?
|
Hypophosphatemia | 1 | 2017 | 4 | 0.150 |
Why?
|
Computational Biology | 2 | 2018 | 214 | 0.150 |
Why?
|
Oligonucleotides, Antisense | 4 | 2005 | 28 | 0.150 |
Why?
|
Infusions, Intravenous | 4 | 2019 | 206 | 0.150 |
Why?
|
Keratitis | 1 | 2017 | 11 | 0.150 |
Why?
|
PTEN Phosphohydrolase | 2 | 2016 | 55 | 0.150 |
Why?
|
Leiomyoma | 1 | 1997 | 25 | 0.150 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2017 | 53 | 0.150 |
Why?
|
Retrospective Studies | 9 | 2021 | 6108 | 0.140 |
Why?
|
Aminopyridines | 1 | 2017 | 15 | 0.140 |
Why?
|
Phenotype | 7 | 2018 | 729 | 0.140 |
Why?
|
Esophageal Neoplasms | 2 | 2009 | 98 | 0.140 |
Why?
|
Protein Kinases | 5 | 1998 | 71 | 0.140 |
Why?
|
Epothilones | 1 | 2016 | 2 | 0.140 |
Why?
|
Catheters, Indwelling | 1 | 2017 | 58 | 0.140 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 3 | 2014 | 34 | 0.140 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2016 | 19 | 0.140 |
Why?
|
Homologous Recombination | 1 | 2017 | 40 | 0.140 |
Why?
|
Aminopterin | 1 | 2016 | 2 | 0.140 |
Why?
|
Glucocorticoids | 1 | 2018 | 219 | 0.140 |
Why?
|
Genetic Therapy | 2 | 2015 | 114 | 0.140 |
Why?
|
Cyclin E | 3 | 2010 | 6 | 0.140 |
Why?
|
Antiemetics | 1 | 2016 | 32 | 0.140 |
Why?
|
Actins | 2 | 2014 | 118 | 0.140 |
Why?
|
Pathology, Molecular | 1 | 2016 | 22 | 0.140 |
Why?
|
Retinoblastoma | 2 | 1995 | 16 | 0.140 |
Why?
|
Megestrol Acetate | 1 | 2016 | 17 | 0.140 |
Why?
|
Triazines | 1 | 2016 | 24 | 0.140 |
Why?
|
Drug Hypersensitivity | 1 | 2016 | 36 | 0.140 |
Why?
|
Tissue Distribution | 1 | 2016 | 163 | 0.140 |
Why?
|
Connective Tissue Growth Factor | 1 | 2015 | 8 | 0.130 |
Why?
|
Mosaicism | 1 | 2016 | 18 | 0.130 |
Why?
|
Protein Isoforms | 1 | 2016 | 119 | 0.130 |
Why?
|
Lymph Node Excision | 1 | 2017 | 134 | 0.130 |
Why?
|
Hypotension | 1 | 2016 | 63 | 0.130 |
Why?
|
Benzodiazepines | 1 | 2016 | 70 | 0.130 |
Why?
|
Cell Adhesion Molecules | 3 | 2017 | 88 | 0.130 |
Why?
|
Vomiting | 1 | 2016 | 75 | 0.130 |
Why?
|
Enzyme Inhibitors | 5 | 2003 | 391 | 0.130 |
Why?
|
Anti-Mullerian Hormone | 1 | 2015 | 4 | 0.130 |
Why?
|
Sirolimus | 1 | 2016 | 62 | 0.130 |
Why?
|
Leukocytes, Mononuclear | 1 | 2016 | 116 | 0.130 |
Why?
|
Interferon-gamma | 3 | 2024 | 177 | 0.130 |
Why?
|
Gene Library | 1 | 2015 | 43 | 0.130 |
Why?
|
Quality Assurance, Health Care | 1 | 2016 | 149 | 0.130 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2015 | 43 | 0.130 |
Why?
|
Early Detection of Cancer | 3 | 2017 | 169 | 0.130 |
Why?
|
Retroviridae Proteins, Oncogenic | 1 | 1994 | 1 | 0.130 |
Why?
|
Troponin C | 1 | 2014 | 2 | 0.120 |
Why?
|
Neoplasm, Residual | 3 | 2017 | 165 | 0.120 |
Why?
|
Chemokine CXCL12 | 2 | 2013 | 32 | 0.120 |
Why?
|
Cytoplasm | 3 | 2005 | 90 | 0.120 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2008 | 69 | 0.120 |
Why?
|
Oncogene Proteins | 3 | 2011 | 17 | 0.120 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 1 | 2014 | 20 | 0.120 |
Why?
|
Papillomaviridae | 3 | 2021 | 102 | 0.120 |
Why?
|
Heat-Shock Proteins | 3 | 2012 | 106 | 0.120 |
Why?
|
Dependovirus | 1 | 2015 | 101 | 0.120 |
Why?
|
Cell Transformation, Viral | 3 | 2000 | 25 | 0.120 |
Why?
|
Carcinoma, Small Cell | 7 | 1996 | 25 | 0.120 |
Why?
|
Genes, Neoplasm | 2 | 2011 | 30 | 0.120 |
Why?
|
Receptors, CXCR4 | 2 | 2011 | 28 | 0.120 |
Why?
|
Hormones | 1 | 2014 | 55 | 0.120 |
Why?
|
Recombinant Proteins | 4 | 2009 | 486 | 0.120 |
Why?
|
Chromosomes, Human, Pair 17 | 3 | 2013 | 36 | 0.120 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2013 | 1 | 0.120 |
Why?
|
Immunoenzyme Techniques | 4 | 2013 | 143 | 0.120 |
Why?
|
LIM-Homeodomain Proteins | 1 | 2013 | 3 | 0.120 |
Why?
|
Adenosylmethionine Decarboxylase | 2 | 2006 | 3 | 0.120 |
Why?
|
Gene Silencing | 4 | 2017 | 119 | 0.110 |
Why?
|
Diffusion of Innovation | 1 | 2014 | 45 | 0.110 |
Why?
|
Loss of Heterozygosity | 3 | 2021 | 77 | 0.110 |
Why?
|
Age Factors | 2 | 2016 | 1087 | 0.110 |
Why?
|
Structure-Activity Relationship | 5 | 2017 | 395 | 0.110 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2014 | 32 | 0.110 |
Why?
|
Mutagenesis, Site-Directed | 5 | 2009 | 99 | 0.110 |
Why?
|
Necrosis | 2 | 2011 | 176 | 0.110 |
Why?
|
Growth Substances | 7 | 1996 | 23 | 0.110 |
Why?
|
Gases | 1 | 2013 | 8 | 0.110 |
Why?
|
Molecular Sequence Annotation | 1 | 2013 | 27 | 0.110 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2013 | 1 | 0.110 |
Why?
|
GPI-Linked Proteins | 2 | 2010 | 29 | 0.110 |
Why?
|
Nitrogen Isotopes | 1 | 2013 | 36 | 0.110 |
Why?
|
Mixed Tumor, Mullerian | 1 | 2012 | 3 | 0.110 |
Why?
|
Measles virus | 3 | 1981 | 8 | 0.110 |
Why?
|
Quantitative Trait Loci | 1 | 2013 | 42 | 0.110 |
Why?
|
Fallopian Tubes | 3 | 2023 | 22 | 0.110 |
Why?
|
Environmental Monitoring | 1 | 2013 | 65 | 0.110 |
Why?
|
Rats, Inbred F344 | 3 | 2003 | 196 | 0.110 |
Why?
|
Receptors, Transforming Growth Factor beta | 3 | 2015 | 25 | 0.110 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2013 | 86 | 0.110 |
Why?
|
Globins | 2 | 2009 | 14 | 0.100 |
Why?
|
Saccharomyces cerevisiae Proteins | 1 | 1994 | 152 | 0.100 |
Why?
|
5-Lipoxygenase-Activating Proteins | 1 | 2012 | 1 | 0.100 |
Why?
|
Endonucleases | 1 | 2012 | 15 | 0.100 |
Why?
|
Ribonuclease III | 2 | 2008 | 12 | 0.100 |
Why?
|
Amyloid Precursor Protein Secretases | 1 | 2012 | 12 | 0.100 |
Why?
|
Dipeptides | 1 | 2012 | 21 | 0.100 |
Why?
|
Interleukin-1alpha | 1 | 2012 | 11 | 0.100 |
Why?
|
Aldehyde Dehydrogenase | 1 | 2011 | 26 | 0.100 |
Why?
|
Hedgehog Proteins | 1 | 2011 | 33 | 0.100 |
Why?
|
Research Design | 1 | 2014 | 344 | 0.100 |
Why?
|
Multicenter Studies as Topic | 2 | 2009 | 84 | 0.100 |
Why?
|
Immunocompetence | 1 | 2011 | 18 | 0.100 |
Why?
|
Rabbits | 3 | 2018 | 370 | 0.100 |
Why?
|
Neoplasms, Experimental | 1 | 2012 | 114 | 0.100 |
Why?
|
Cell Hypoxia | 1 | 2011 | 82 | 0.090 |
Why?
|
Phenylurea Compounds | 1 | 2010 | 15 | 0.090 |
Why?
|
Wnt Proteins | 1 | 2011 | 100 | 0.090 |
Why?
|
Liver Neoplasms | 3 | 2013 | 326 | 0.090 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2010 | 8 | 0.090 |
Why?
|
Respiratory Mucosa | 1 | 2010 | 10 | 0.090 |
Why?
|
Vinblastine | 2 | 2020 | 23 | 0.090 |
Why?
|
Computer Simulation | 3 | 2022 | 280 | 0.090 |
Why?
|
STAT3 Transcription Factor | 1 | 2011 | 81 | 0.090 |
Why?
|
Endometriosis | 1 | 2010 | 14 | 0.090 |
Why?
|
Hong Kong | 2 | 2009 | 7 | 0.090 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 2010 | 25 | 0.090 |
Why?
|
Mitochondria | 2 | 2024 | 402 | 0.090 |
Why?
|
Genomic Instability | 2 | 2021 | 92 | 0.090 |
Why?
|
Oxidative Stress | 2 | 2013 | 770 | 0.090 |
Why?
|
Membrane Glycoproteins | 2 | 2004 | 240 | 0.090 |
Why?
|
Glucose | 2 | 2011 | 344 | 0.090 |
Why?
|
I-kappa B Kinase | 1 | 2010 | 20 | 0.090 |
Why?
|
Genetic Association Studies | 1 | 2011 | 117 | 0.090 |
Why?
|
Elafin | 1 | 2010 | 1 | 0.090 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2010 | 55 | 0.090 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2010 | 11 | 0.090 |
Why?
|
Arterial Occlusive Diseases | 2 | 2001 | 79 | 0.090 |
Why?
|
Cell Growth Processes | 4 | 2012 | 22 | 0.090 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 4 | 2012 | 66 | 0.090 |
Why?
|
Kinetics | 4 | 2013 | 623 | 0.090 |
Why?
|
Lung | 2 | 2024 | 486 | 0.090 |
Why?
|
Patient Selection | 2 | 2014 | 253 | 0.090 |
Why?
|
Risk Assessment | 3 | 2021 | 1259 | 0.090 |
Why?
|
Academic Medical Centers | 1 | 2010 | 144 | 0.090 |
Why?
|
Bronchioles | 1 | 2009 | 2 | 0.090 |
Why?
|
Chromosome Deletion | 5 | 2013 | 140 | 0.090 |
Why?
|
Matrix Metalloproteinase 7 | 1 | 2009 | 10 | 0.090 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2009 | 46 | 0.090 |
Why?
|
Ceramides | 3 | 2003 | 28 | 0.090 |
Why?
|
Pulmonary Alveoli | 1 | 2009 | 19 | 0.090 |
Why?
|
Chemokine CXCL2 | 1 | 2009 | 12 | 0.090 |
Why?
|
Receptors, Interleukin-8B | 1 | 2009 | 4 | 0.090 |
Why?
|
Karyopherins | 1 | 2009 | 4 | 0.080 |
Why?
|
NFATC Transcription Factors | 2 | 2007 | 23 | 0.080 |
Why?
|
Genes | 2 | 1988 | 33 | 0.080 |
Why?
|
Apolipoprotein A-I | 1 | 2009 | 7 | 0.080 |
Why?
|
Transferrin | 1 | 2009 | 12 | 0.080 |
Why?
|
Oxidation-Reduction | 2 | 2021 | 322 | 0.080 |
Why?
|
Single-Cell Analysis | 2 | 2020 | 57 | 0.080 |
Why?
|
Prealbumin | 1 | 2009 | 21 | 0.080 |
Why?
|
Models, Genetic | 2 | 2011 | 170 | 0.080 |
Why?
|
HLA-D Antigens | 1 | 2008 | 4 | 0.080 |
Why?
|
Organoids | 1 | 2009 | 39 | 0.080 |
Why?
|
Alleles | 3 | 2017 | 250 | 0.080 |
Why?
|
Exons | 3 | 2016 | 95 | 0.080 |
Why?
|
Endoribonucleases | 1 | 2008 | 15 | 0.080 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2009 | 64 | 0.080 |
Why?
|
Aspartate-Ammonia Ligase | 1 | 2008 | 1 | 0.080 |
Why?
|
Asparaginase | 1 | 2008 | 3 | 0.080 |
Why?
|
Neuropeptides | 3 | 1998 | 37 | 0.080 |
Why?
|
Clusterin | 1 | 2008 | 6 | 0.080 |
Why?
|
Protease Inhibitors | 1 | 2009 | 58 | 0.080 |
Why?
|
Cyclophosphamide | 1 | 2009 | 165 | 0.080 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2008 | 65 | 0.080 |
Why?
|
Receptors, Progesterone | 2 | 2013 | 63 | 0.080 |
Why?
|
DEAD-box RNA Helicases | 1 | 2008 | 34 | 0.080 |
Why?
|
Response Elements | 2 | 2009 | 29 | 0.080 |
Why?
|
Polyethylene Glycols | 2 | 2019 | 93 | 0.080 |
Why?
|
Contact Inhibition | 2 | 2006 | 3 | 0.080 |
Why?
|
Confidence Intervals | 3 | 2017 | 156 | 0.080 |
Why?
|
Treatment Failure | 1 | 2008 | 114 | 0.080 |
Why?
|
Multigene Family | 2 | 2007 | 56 | 0.080 |
Why?
|
Estrogen Antagonists | 2 | 1999 | 21 | 0.080 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2008 | 25 | 0.080 |
Why?
|
Calcineurin | 1 | 2009 | 71 | 0.080 |
Why?
|
Phosphoric Monoester Hydrolases | 2 | 2002 | 22 | 0.080 |
Why?
|
Oncogene Proteins, Viral | 2 | 2000 | 52 | 0.080 |
Why?
|
Mollusca | 1 | 2007 | 2 | 0.080 |
Why?
|
Hydroquinones | 1 | 2007 | 3 | 0.080 |
Why?
|
Quinones | 1 | 2007 | 8 | 0.080 |
Why?
|
Multivariate Analysis | 4 | 2014 | 577 | 0.080 |
Why?
|
Myocytes, Cardiac | 1 | 2009 | 125 | 0.080 |
Why?
|
Polymorphism, Restriction Fragment Length | 3 | 1997 | 66 | 0.080 |
Why?
|
Drug Therapy, Combination | 2 | 2021 | 377 | 0.070 |
Why?
|
Jaundice | 1 | 1987 | 19 | 0.070 |
Why?
|
RNA | 3 | 2002 | 170 | 0.070 |
Why?
|
Combined Modality Therapy | 4 | 2012 | 637 | 0.070 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2007 | 8 | 0.070 |
Why?
|
Drug Discovery | 3 | 2016 | 85 | 0.070 |
Why?
|
ROC Curve | 2 | 2018 | 232 | 0.070 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2007 | 17 | 0.070 |
Why?
|
Mice, Inbred BALB C | 4 | 2017 | 304 | 0.070 |
Why?
|
Matrix Metalloproteinases | 1 | 2007 | 48 | 0.070 |
Why?
|
Gene Knockdown Techniques | 3 | 2012 | 106 | 0.070 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 83 | 0.070 |
Why?
|
Sequence Deletion | 4 | 1996 | 66 | 0.070 |
Why?
|
Vitamin E | 2 | 1998 | 81 | 0.070 |
Why?
|
Ornithine Decarboxylase | 2 | 2004 | 12 | 0.070 |
Why?
|
Intention to Treat Analysis | 2 | 2017 | 27 | 0.070 |
Why?
|
Health Status Disparities | 1 | 2009 | 195 | 0.070 |
Why?
|
Growth Inhibitors | 2 | 2007 | 27 | 0.070 |
Why?
|
Hodgkin Disease | 1 | 1987 | 44 | 0.070 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1987 | 60 | 0.070 |
Why?
|
Erythropoiesis | 2 | 2004 | 16 | 0.070 |
Why?
|
Protein Kinase C | 3 | 1998 | 71 | 0.070 |
Why?
|
Remission Induction | 2 | 2018 | 207 | 0.070 |
Why?
|
Eye Proteins | 1 | 2006 | 17 | 0.070 |
Why?
|
NIH 3T3 Cells | 4 | 2009 | 52 | 0.070 |
Why?
|
Cell Communication | 1 | 2006 | 69 | 0.070 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2006 | 36 | 0.070 |
Why?
|
Thymosin | 1 | 2006 | 2 | 0.070 |
Why?
|
DNA Damage | 4 | 2021 | 301 | 0.070 |
Why?
|
Decision Trees | 1 | 2006 | 19 | 0.070 |
Why?
|
G1 Phase | 2 | 2008 | 14 | 0.070 |
Why?
|
Skin Neoplasms | 2 | 2006 | 488 | 0.070 |
Why?
|
Liver | 3 | 2000 | 1115 | 0.070 |
Why?
|
Diagnosis, Differential | 2 | 2006 | 1037 | 0.070 |
Why?
|
DNA Repair | 2 | 2017 | 193 | 0.070 |
Why?
|
Retinoids | 2 | 2004 | 6 | 0.070 |
Why?
|
Embryo, Mammalian | 4 | 2007 | 66 | 0.070 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2005 | 34 | 0.070 |
Why?
|
Cross-Sectional Studies | 1 | 2011 | 1557 | 0.070 |
Why?
|
Cyclin A2 | 1 | 2005 | 1 | 0.060 |
Why?
|
Meta-Analysis as Topic | 2 | 2017 | 39 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 2 | 2021 | 1159 | 0.060 |
Why?
|
Amino Acid Sequence | 7 | 2007 | 585 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2007 | 176 | 0.060 |
Why?
|
Image Enhancement | 1 | 2005 | 54 | 0.060 |
Why?
|
Carotid Arteries | 1 | 2005 | 85 | 0.060 |
Why?
|
Matrix Metalloproteinases, Membrane-Associated | 1 | 2004 | 3 | 0.060 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 3 | 2000 | 51 | 0.060 |
Why?
|
Endometrium | 2 | 2019 | 41 | 0.060 |
Why?
|
Fluorescent Antibody Technique | 3 | 2009 | 108 | 0.060 |
Why?
|
Magnetic Resonance Angiography | 1 | 2005 | 77 | 0.060 |
Why?
|
Staining and Labeling | 3 | 2008 | 97 | 0.060 |
Why?
|
Cystadenocarcinoma, Mucinous | 1 | 2004 | 2 | 0.060 |
Why?
|
Vascular Patency | 2 | 2002 | 82 | 0.060 |
Why?
|
Creatinine | 2 | 2002 | 139 | 0.060 |
Why?
|
Temperature | 3 | 2013 | 168 | 0.060 |
Why?
|
Retinoid X Receptors | 1 | 2004 | 13 | 0.060 |
Why?
|
Metalloendopeptidases | 1 | 2004 | 70 | 0.060 |
Why?
|
Mouth Neoplasms | 1 | 2004 | 20 | 0.060 |
Why?
|
Carcinogens | 3 | 1996 | 199 | 0.060 |
Why?
|
Lasers | 1 | 2004 | 123 | 0.060 |
Why?
|
Consensus | 2 | 2018 | 148 | 0.060 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2004 | 73 | 0.060 |
Why?
|
Disease Susceptibility | 2 | 2018 | 89 | 0.060 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 26 | 0.060 |
Why?
|
Antibodies, Viral | 2 | 1981 | 88 | 0.060 |
Why?
|
Pathology | 1 | 2004 | 33 | 0.060 |
Why?
|
Hypertension | 2 | 2019 | 533 | 0.060 |
Why?
|
Urea | 1 | 2004 | 77 | 0.060 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2024 | 107 | 0.060 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2000 | 55 | 0.060 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2004 | 49 | 0.060 |
Why?
|
Isoenzymes | 1 | 2004 | 168 | 0.060 |
Why?
|
Hyperoxia | 1 | 2003 | 26 | 0.060 |
Why?
|
Dexamethasone | 2 | 2016 | 430 | 0.060 |
Why?
|
Genetic Vectors | 3 | 2003 | 125 | 0.060 |
Why?
|
Vimentin | 2 | 2000 | 32 | 0.060 |
Why?
|
Transcription Factor RelA | 3 | 2010 | 29 | 0.060 |
Why?
|
Receptors, Scavenger | 1 | 2023 | 29 | 0.060 |
Why?
|
Wnt Signaling Pathway | 1 | 2024 | 92 | 0.060 |
Why?
|
Women's Health | 1 | 2003 | 90 | 0.060 |
Why?
|
Repressor Proteins | 1 | 2004 | 151 | 0.060 |
Why?
|
Taxoids | 2 | 2014 | 37 | 0.050 |
Why?
|
Tuberculosis | 1 | 2024 | 146 | 0.050 |
Why?
|
Luminescent Proteins | 1 | 2003 | 53 | 0.050 |
Why?
|
Precipitin Tests | 3 | 1991 | 32 | 0.050 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2023 | 38 | 0.050 |
Why?
|
Hematopoietic Stem Cells | 1 | 2004 | 184 | 0.050 |
Why?
|
Host-Pathogen Interactions | 1 | 2024 | 134 | 0.050 |
Why?
|
Vasoactive Intestinal Peptide | 3 | 1998 | 17 | 0.050 |
Why?
|
Dual Specificity Phosphatase 1 | 1 | 2002 | 9 | 0.050 |
Why?
|
Protein Phosphatase 1 | 1 | 2002 | 7 | 0.050 |
Why?
|
Causality | 1 | 2022 | 44 | 0.050 |
Why?
|
Gamma Rays | 1 | 2002 | 49 | 0.050 |
Why?
|
Melanoma | 1 | 2006 | 285 | 0.050 |
Why?
|
Antigens, Viral | 2 | 1981 | 44 | 0.050 |
Why?
|
Caspases | 4 | 2004 | 104 | 0.050 |
Why?
|
Chromosome Mapping | 2 | 2013 | 156 | 0.050 |
Why?
|
Blood Pressure | 2 | 2002 | 512 | 0.050 |
Why?
|
Acetyl-CoA Carboxylase | 1 | 2021 | 13 | 0.050 |
Why?
|
Allelic Imbalance | 1 | 2021 | 3 | 0.050 |
Why?
|
Wound Healing | 2 | 2017 | 204 | 0.050 |
Why?
|
Anticarcinogenic Agents | 2 | 1992 | 34 | 0.050 |
Why?
|
Research Support as Topic | 2 | 2014 | 46 | 0.050 |
Why?
|
Oxidative Phosphorylation | 1 | 2021 | 39 | 0.050 |
Why?
|
Sex Chromosome Aberrations | 1 | 2001 | 8 | 0.050 |
Why?
|
Matrix Metalloproteinase 9 | 2 | 2013 | 88 | 0.050 |
Why?
|
Induction Chemotherapy | 1 | 2021 | 60 | 0.050 |
Why?
|
Ki-67 Antigen | 2 | 2012 | 57 | 0.050 |
Why?
|
Graft Occlusion, Vascular | 1 | 2002 | 73 | 0.050 |
Why?
|
Subcellular Fractions | 1 | 2001 | 34 | 0.050 |
Why?
|
Endothelial Cells | 2 | 2017 | 269 | 0.050 |
Why?
|
Blood Vessel Prosthesis | 1 | 2002 | 85 | 0.050 |
Why?
|
Injections, Intravenous | 2 | 2015 | 140 | 0.050 |
Why?
|
Breast | 2 | 2002 | 85 | 0.050 |
Why?
|
Cerebral Infarction | 1 | 2001 | 39 | 0.050 |
Why?
|
Microscopy, Fluorescence | 2 | 2013 | 162 | 0.050 |
Why?
|
Fatty Acids | 1 | 2021 | 146 | 0.050 |
Why?
|
Ectoderm | 1 | 2000 | 1 | 0.050 |
Why?
|
Lovastatin | 1 | 2000 | 9 | 0.050 |
Why?
|
Gene Expression Regulation, Enzymologic | 2 | 2007 | 181 | 0.050 |
Why?
|
Diabetic Foot | 1 | 2001 | 51 | 0.050 |
Why?
|
T-Lymphocytes | 2 | 2020 | 338 | 0.050 |
Why?
|
Activin Receptors, Type I | 1 | 2000 | 2 | 0.050 |
Why?
|
Gene Regulatory Networks | 1 | 2021 | 107 | 0.050 |
Why?
|
Ploidies | 1 | 2020 | 11 | 0.050 |
Why?
|
Sphingosine | 2 | 1997 | 26 | 0.050 |
Why?
|
Stress, Mechanical | 1 | 2021 | 88 | 0.050 |
Why?
|
Human papillomavirus 18 | 1 | 2020 | 9 | 0.050 |
Why?
|
Mice, Knockout | 2 | 2017 | 841 | 0.050 |
Why?
|
Receptors, Pituitary Hormone | 2 | 1998 | 2 | 0.050 |
Why?
|
Prosthesis Failure | 1 | 2001 | 107 | 0.050 |
Why?
|
DNA, Complementary | 3 | 2005 | 135 | 0.050 |
Why?
|
Risk | 2 | 2012 | 320 | 0.050 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2012 | 79 | 0.050 |
Why?
|
Arteriosclerosis | 1 | 2000 | 54 | 0.050 |
Why?
|
Alternative Splicing | 2 | 2016 | 56 | 0.040 |
Why?
|
G2 Phase | 1 | 2000 | 13 | 0.040 |
Why?
|
Human papillomavirus 16 | 1 | 2020 | 44 | 0.040 |
Why?
|
Cervix Uteri | 1 | 2000 | 49 | 0.040 |
Why?
|
Phorbol Esters | 1 | 2000 | 3 | 0.040 |
Why?
|
DNA Footprinting | 1 | 2000 | 8 | 0.040 |
Why?
|
RNA-Binding Proteins | 2 | 2011 | 123 | 0.040 |
Why?
|
CDC2-CDC28 Kinases | 1 | 2000 | 12 | 0.040 |
Why?
|
Bleomycin | 1 | 2020 | 35 | 0.040 |
Why?
|
Chemoradiotherapy | 1 | 2020 | 40 | 0.040 |
Why?
|
Diamines | 1 | 2019 | 4 | 0.040 |
Why?
|
Azacitidine | 1 | 2019 | 34 | 0.040 |
Why?
|
Leg | 1 | 2000 | 122 | 0.040 |
Why?
|
Deoxycytidine | 1 | 2019 | 27 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2019 | 17 | 0.040 |
Why?
|
Deoxyribonuclease I | 1 | 2000 | 34 | 0.040 |
Why?
|
Ligands | 2 | 2000 | 204 | 0.040 |
Why?
|
Antigens, Neoplasm | 2 | 2009 | 151 | 0.040 |
Why?
|
Thrombectomy | 1 | 2000 | 67 | 0.040 |
Why?
|
Blotting, Southern | 2 | 1997 | 42 | 0.040 |
Why?
|
Anemia, Aplastic | 1 | 2019 | 12 | 0.040 |
Why?
|
Adiposity | 1 | 2021 | 127 | 0.040 |
Why?
|
Moloney murine leukemia virus | 2 | 1989 | 2 | 0.040 |
Why?
|
Proteinuria | 1 | 2019 | 39 | 0.040 |
Why?
|
Viral Proteins | 1 | 1981 | 155 | 0.040 |
Why?
|
Thrombolytic Therapy | 1 | 2000 | 110 | 0.040 |
Why?
|
Chloramphenicol O-Acetyltransferase | 1 | 1999 | 8 | 0.040 |
Why?
|
Immunoassay | 1 | 2019 | 20 | 0.040 |
Why?
|
Mullerian Ducts | 1 | 2019 | 4 | 0.040 |
Why?
|
Infusions, Parenteral | 1 | 2019 | 11 | 0.040 |
Why?
|
Onium Compounds | 1 | 1999 | 13 | 0.040 |
Why?
|
Drug Monitoring | 1 | 2019 | 77 | 0.040 |
Why?
|
Models, Economic | 1 | 2018 | 17 | 0.040 |
Why?
|
Toxicity Tests, Subacute | 1 | 2018 | 1 | 0.040 |
Why?
|
Patient Safety | 1 | 2019 | 102 | 0.040 |
Why?
|
Ophthalmic Solutions | 1 | 2018 | 18 | 0.040 |
Why?
|
Gene Deletion | 2 | 2004 | 266 | 0.040 |
Why?
|
Morphogenesis | 1 | 2018 | 16 | 0.040 |
Why?
|
Ovariectomy | 1 | 2019 | 119 | 0.040 |
Why?
|
Pyrazoles | 1 | 2019 | 113 | 0.040 |
Why?
|
Erythroid Precursor Cells | 1 | 1998 | 15 | 0.040 |
Why?
|
Acetylcysteine | 1 | 1999 | 100 | 0.040 |
Why?
|
Cornea | 1 | 2018 | 52 | 0.040 |
Why?
|
Blood Glucose | 1 | 2001 | 439 | 0.040 |
Why?
|
Lymphoma | 1 | 1999 | 66 | 0.040 |
Why?
|
Protein Structure, Tertiary | 3 | 2006 | 253 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2018 | 144 | 0.040 |
Why?
|
Electrophoresis, Agar Gel | 1 | 1998 | 11 | 0.040 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 91 | 0.040 |
Why?
|
Focal Adhesions | 1 | 2017 | 14 | 0.040 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2018 | 138 | 0.040 |
Why?
|
Neuropilin-1 | 1 | 2017 | 2 | 0.040 |
Why?
|
Receptor, TIE-2 | 1 | 2017 | 16 | 0.040 |
Why?
|
Flavonoids | 1 | 1998 | 58 | 0.040 |
Why?
|
Receptors, Androgen | 1 | 1998 | 46 | 0.040 |
Why?
|
Integrins | 1 | 2017 | 31 | 0.040 |
Why?
|
Permeability | 1 | 2017 | 68 | 0.040 |
Why?
|
Estrogens | 1 | 1999 | 227 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2017 | 32 | 0.040 |
Why?
|
Endothelium, Vascular | 1 | 1999 | 252 | 0.040 |
Why?
|
Calcium-Binding Proteins | 1 | 2017 | 54 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2017 | 20 | 0.040 |
Why?
|
Microcirculation | 1 | 2017 | 70 | 0.040 |
Why?
|
Chitosan | 1 | 2017 | 34 | 0.040 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 1 | 1998 | 61 | 0.040 |
Why?
|
Aging | 1 | 2002 | 687 | 0.040 |
Why?
|
Mice, Transgenic | 2 | 2009 | 555 | 0.040 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 1997 | 19 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 1997 | 12 | 0.040 |
Why?
|
Myocardial Infarction | 1 | 2001 | 389 | 0.040 |
Why?
|
Telomere-Binding Proteins | 1 | 2017 | 4 | 0.040 |
Why?
|
DNA Probes, HPV | 1 | 1997 | 3 | 0.040 |
Why?
|
Micelles | 1 | 2017 | 8 | 0.040 |
Why?
|
Neurons | 1 | 2000 | 460 | 0.040 |
Why?
|
Thrombosis | 1 | 2000 | 248 | 0.040 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2017 | 30 | 0.040 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 244 | 0.040 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 2 | 1991 | 102 | 0.040 |
Why?
|
Quality of Health Care | 1 | 2018 | 186 | 0.040 |
Why?
|
MCF-7 Cells | 1 | 2017 | 68 | 0.040 |
Why?
|
Hysterectomy | 1 | 2017 | 88 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2011 | 375 | 0.040 |
Why?
|
Drug Evaluation | 1 | 1996 | 26 | 0.040 |
Why?
|
Receptors, Vasoactive Intestinal Peptide | 1 | 1996 | 3 | 0.040 |
Why?
|
Tubulin | 1 | 2016 | 23 | 0.040 |
Why?
|
Transformation, Genetic | 1 | 1996 | 16 | 0.040 |
Why?
|
Tubulin Modulators | 1 | 2016 | 31 | 0.040 |
Why?
|
Laparoscopy | 1 | 2018 | 170 | 0.030 |
Why?
|
Ondansetron | 1 | 2016 | 13 | 0.030 |
Why?
|
Dimerization | 1 | 1996 | 52 | 0.030 |
Why?
|
Tretinoin | 2 | 1994 | 53 | 0.030 |
Why?
|
Phenanthridines | 1 | 1996 | 4 | 0.030 |
Why?
|
Propensity Score | 1 | 2017 | 123 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 1997 | 237 | 0.030 |
Why?
|
Administration, Intravenous | 1 | 2016 | 69 | 0.030 |
Why?
|
NF-kappa B p50 Subunit | 2 | 2010 | 17 | 0.030 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 1996 | 11 | 0.030 |
Why?
|
Postmenopause | 2 | 2009 | 100 | 0.030 |
Why?
|
Computers, Molecular | 1 | 2016 | 1 | 0.030 |
Why?
|
G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 7 | 0.030 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 1996 | 37 | 0.030 |
Why?
|
Cytarabine | 1 | 1996 | 39 | 0.030 |
Why?
|
Oncogene Proteins v-mos | 1 | 1995 | 1 | 0.030 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 1995 | 5 | 0.030 |
Why?
|
Cocarcinogenesis | 1 | 1996 | 14 | 0.030 |
Why?
|
Cloning, Molecular | 2 | 1994 | 185 | 0.030 |
Why?
|
Molecular Structure | 1 | 2017 | 297 | 0.030 |
Why?
|
Cause of Death | 1 | 2017 | 143 | 0.030 |
Why?
|
Ultraviolet Rays | 2 | 2008 | 51 | 0.030 |
Why?
|
Conserved Sequence | 2 | 2006 | 56 | 0.030 |
Why?
|
Miniaturization | 1 | 2015 | 6 | 0.030 |
Why?
|
Leukopenia | 1 | 2015 | 7 | 0.030 |
Why?
|
Drug Compounding | 1 | 2015 | 24 | 0.030 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 3 | 2000 | 14 | 0.030 |
Why?
|
Tropism | 1 | 2015 | 2 | 0.030 |
Why?
|
Inflammation | 2 | 2012 | 604 | 0.030 |
Why?
|
Receptors, Peptide | 1 | 2015 | 11 | 0.030 |
Why?
|
Glioblastoma | 1 | 1997 | 92 | 0.030 |
Why?
|
Drug Implants | 1 | 2015 | 35 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2015 | 25 | 0.030 |
Why?
|
Solubility | 1 | 2015 | 69 | 0.030 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 1995 | 39 | 0.030 |
Why?
|
Small Molecule Libraries | 1 | 2016 | 68 | 0.030 |
Why?
|
Transgenes | 1 | 2015 | 55 | 0.030 |
Why?
|
Protein Transport | 1 | 2016 | 180 | 0.030 |
Why?
|
Bombesin | 1 | 1995 | 2 | 0.030 |
Why?
|
Naphthalenes | 1 | 1996 | 121 | 0.030 |
Why?
|
Oncogene Proteins v-raf | 1 | 1994 | 1 | 0.030 |
Why?
|
Muscles | 1 | 2015 | 103 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 1 | 1999 | 1597 | 0.030 |
Why?
|
Genetic Complementation Test | 2 | 1988 | 47 | 0.030 |
Why?
|
Algorithms | 1 | 2018 | 615 | 0.030 |
Why?
|
Models, Molecular | 1 | 2016 | 338 | 0.030 |
Why?
|
Smoking | 2 | 1996 | 511 | 0.030 |
Why?
|
Interleukin-2 | 1 | 1994 | 72 | 0.030 |
Why?
|
Estradiol | 1 | 1996 | 225 | 0.030 |
Why?
|
Leucine Zippers | 1 | 1994 | 1 | 0.030 |
Why?
|
Fluorescent Dyes | 1 | 2014 | 102 | 0.030 |
Why?
|
Drug Industry | 1 | 2014 | 38 | 0.030 |
Why?
|
Teratocarcinoma | 1 | 1993 | 1 | 0.030 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2013 | 15 | 0.030 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2009 | 191 | 0.030 |
Why?
|
Cystadenoma | 1 | 1993 | 3 | 0.030 |
Why?
|
DNA Methylation | 2 | 2010 | 548 | 0.030 |
Why?
|
Weight Loss | 1 | 2015 | 237 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 1995 | 164 | 0.030 |
Why?
|
RNA Splicing | 2 | 1991 | 37 | 0.030 |
Why?
|
Capsules | 1 | 2013 | 30 | 0.030 |
Why?
|
Cell Shape | 1 | 2013 | 20 | 0.030 |
Why?
|
Smad Proteins | 1 | 2013 | 11 | 0.030 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 22 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2013 | 96 | 0.030 |
Why?
|
Genes, Suppressor | 1 | 1993 | 2 | 0.030 |
Why?
|
Software Design | 1 | 2013 | 12 | 0.030 |
Why?
|
Nitrogen Oxides | 1 | 2013 | 3 | 0.030 |
Why?
|
Ice | 1 | 2013 | 3 | 0.030 |
Why?
|
Atmosphere | 1 | 2013 | 9 | 0.030 |
Why?
|
Adsorption | 1 | 2013 | 17 | 0.030 |
Why?
|
Oxidants | 2 | 2003 | 53 | 0.030 |
Why?
|
DNA Fragmentation | 2 | 2004 | 55 | 0.030 |
Why?
|
Injections, Intraperitoneal | 1 | 2013 | 54 | 0.030 |
Why?
|
Binding, Competitive | 1 | 1993 | 94 | 0.030 |
Why?
|
Thermodynamics | 1 | 2013 | 34 | 0.030 |
Why?
|
Extracellular Matrix Proteins | 1 | 2013 | 69 | 0.030 |
Why?
|
Pituitary Adenylate Cyclase-Activating Polypeptide | 3 | 1998 | 13 | 0.030 |
Why?
|
Plasmids | 2 | 1994 | 161 | 0.030 |
Why?
|
Gene-Environment Interaction | 1 | 2013 | 36 | 0.030 |
Why?
|
Fungal Proteins | 1 | 1994 | 118 | 0.030 |
Why?
|
DNA, Single-Stranded | 1 | 1993 | 87 | 0.030 |
Why?
|
Pressure | 1 | 2013 | 105 | 0.030 |
Why?
|
Polymorphism, Genetic | 1 | 1993 | 181 | 0.030 |
Why?
|
Calcium | 1 | 2014 | 396 | 0.030 |
Why?
|
Leukemia, Erythroblastic, Acute | 1 | 1992 | 4 | 0.030 |
Why?
|
Australia | 1 | 2012 | 83 | 0.030 |
Why?
|
Medical History Taking | 1 | 2012 | 47 | 0.030 |
Why?
|
Oncogene Protein p21(ras) | 1 | 1991 | 3 | 0.030 |
Why?
|
Administration, Oral | 1 | 2013 | 426 | 0.030 |
Why?
|
Veratrum Alkaloids | 1 | 2011 | 5 | 0.030 |
Why?
|
Mass Screening | 1 | 1995 | 353 | 0.030 |
Why?
|
Retinal Dehydrogenase | 1 | 2011 | 10 | 0.030 |
Why?
|
Carbohydrate Metabolism | 1 | 1992 | 26 | 0.030 |
Why?
|
Equipment Design | 1 | 2013 | 284 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-raf | 2 | 2003 | 7 | 0.030 |
Why?
|
Classification | 1 | 2011 | 14 | 0.030 |
Why?
|
Granulocytes | 1 | 1991 | 26 | 0.030 |
Why?
|
Cytodiagnosis | 1 | 1992 | 42 | 0.020 |
Why?
|
Frozen Sections | 1 | 2011 | 13 | 0.020 |
Why?
|
Caspase 3 | 2 | 2003 | 97 | 0.020 |
Why?
|
Biopsy | 1 | 2013 | 584 | 0.020 |
Why?
|
Cell Dedifferentiation | 1 | 2011 | 9 | 0.020 |
Why?
|
Cyclin-Dependent Kinases | 2 | 2003 | 28 | 0.020 |
Why?
|
Hematopoiesis | 1 | 1991 | 71 | 0.020 |
Why?
|
Genetic Testing | 1 | 1992 | 119 | 0.020 |
Why?
|
Estrous Cycle | 1 | 2011 | 5 | 0.020 |
Why?
|
Adenoviridae | 2 | 2003 | 51 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2011 | 51 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2013 | 228 | 0.020 |
Why?
|
Hydrogen Peroxide | 2 | 2003 | 115 | 0.020 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2011 | 181 | 0.020 |
Why?
|
Cell Count | 1 | 2011 | 147 | 0.020 |
Why?
|
Texas | 1 | 2011 | 137 | 0.020 |
Why?
|
COS Cells | 2 | 2003 | 74 | 0.020 |
Why?
|
3' Untranslated Regions | 1 | 2011 | 52 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2011 | 183 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-myb | 1 | 2010 | 8 | 0.020 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2010 | 25 | 0.020 |
Why?
|
International Cooperation | 1 | 2010 | 44 | 0.020 |
Why?
|
Transcription Factor RelB | 1 | 2010 | 2 | 0.020 |
Why?
|
Carbolines | 1 | 2010 | 3 | 0.020 |
Why?
|
Adenoma | 1 | 1992 | 110 | 0.020 |
Why?
|
Amino Acid Chloromethyl Ketones | 2 | 2000 | 10 | 0.020 |
Why?
|
Cricetulus | 1 | 2010 | 97 | 0.020 |
Why?
|
HeLa Cells | 1 | 2011 | 250 | 0.020 |
Why?
|
Caspase Inhibitors | 2 | 2000 | 16 | 0.020 |
Why?
|
CHO Cells | 1 | 2010 | 120 | 0.020 |
Why?
|
Atrial Natriuretic Factor | 1 | 1990 | 21 | 0.020 |
Why?
|
Cricetinae | 1 | 2010 | 192 | 0.020 |
Why?
|
Child | 1 | 2022 | 6847 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 2 | 2000 | 50 | 0.020 |
Why?
|
Minority Health | 1 | 2009 | 10 | 0.020 |
Why?
|
Financing, Government | 1 | 2009 | 23 | 0.020 |
Why?
|
Guanosine Triphosphate | 2 | 2000 | 19 | 0.020 |
Why?
|
Ovarian Cysts | 1 | 2009 | 4 | 0.020 |
Why?
|
Mucin-1 | 1 | 2009 | 3 | 0.020 |
Why?
|
Chemokine CXCL1 | 1 | 2009 | 3 | 0.020 |
Why?
|
Sodium Salicylate | 1 | 2009 | 4 | 0.020 |
Why?
|
HCT116 Cells | 1 | 2009 | 22 | 0.020 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1989 | 48 | 0.020 |
Why?
|
Gastrin-Releasing Peptide | 3 | 1995 | 4 | 0.020 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2009 | 75 | 0.020 |
Why?
|
Acetamides | 1 | 1989 | 20 | 0.020 |
Why?
|
Suppression, Genetic | 1 | 1989 | 3 | 0.020 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 1989 | 96 | 0.020 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2009 | 39 | 0.020 |
Why?
|
Genes, erbB-1 | 1 | 2008 | 8 | 0.020 |
Why?
|
Leukemia, Myeloid | 2 | 2000 | 43 | 0.020 |
Why?
|
Sequence Alignment | 1 | 2009 | 121 | 0.020 |
Why?
|
Chromones | 1 | 2008 | 21 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2009 | 99 | 0.020 |
Why?
|
DNA Fingerprinting | 1 | 2008 | 62 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2009 | 112 | 0.020 |
Why?
|
Reference Values | 1 | 2009 | 310 | 0.020 |
Why?
|
Papillomavirus E7 Proteins | 2 | 2000 | 31 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 1 | 2009 | 151 | 0.020 |
Why?
|
Stomach Neoplasms | 1 | 1991 | 174 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2008 | 105 | 0.020 |
Why?
|
Sex Factors | 1 | 2010 | 691 | 0.020 |
Why?
|
Tocopherols | 2 | 1998 | 7 | 0.020 |
Why?
|
Luteinizing Hormone | 1 | 2008 | 49 | 0.020 |
Why?
|
Aldehyde Reductase | 1 | 2007 | 3 | 0.020 |
Why?
|
GABA Plasma Membrane Transport Proteins | 1 | 2007 | 3 | 0.020 |
Why?
|
Aquaporin 2 | 1 | 2007 | 5 | 0.020 |
Why?
|
Follicle Stimulating Hormone | 1 | 2008 | 43 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2008 | 74 | 0.020 |
Why?
|
Symporters | 1 | 2007 | 17 | 0.020 |
Why?
|
RNA Processing, Post-Transcriptional | 1 | 1988 | 24 | 0.020 |
Why?
|
Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide | 2 | 1998 | 2 | 0.020 |
Why?
|
Free Radical Scavengers | 1 | 2007 | 25 | 0.020 |
Why?
|
Matrix Metalloproteinase 3 | 1 | 2007 | 19 | 0.020 |
Why?
|
Sodium Chloride | 1 | 2007 | 57 | 0.020 |
Why?
|
HSP70 Heat-Shock Proteins | 1 | 2007 | 62 | 0.020 |
Why?
|
Matrix Metalloproteinase 14 | 1 | 2007 | 5 | 0.020 |
Why?
|
Dogs | 1 | 2007 | 182 | 0.020 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2007 | 57 | 0.020 |
Why?
|
Serum Response Element | 1 | 2006 | 4 | 0.020 |
Why?
|
Two-Hybrid System Techniques | 1 | 2006 | 24 | 0.020 |
Why?
|
Cyclic AMP | 2 | 1998 | 90 | 0.020 |
Why?
|
Organ Specificity | 1 | 2007 | 108 | 0.020 |
Why?
|
Oligopeptides | 2 | 1999 | 89 | 0.020 |
Why?
|
Iodine Radioisotopes | 2 | 1997 | 35 | 0.020 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2007 | 106 | 0.020 |
Why?
|
Collagen | 1 | 2007 | 206 | 0.020 |
Why?
|
Basic-Leucine Zipper Transcription Factors | 2 | 1998 | 12 | 0.020 |
Why?
|
Forecasting | 1 | 2006 | 150 | 0.020 |
Why?
|
Epidermal Growth Factor | 2 | 1997 | 34 | 0.020 |
Why?
|
Cell Nucleolus | 1 | 2005 | 4 | 0.020 |
Why?
|
Serine | 2 | 1998 | 37 | 0.020 |
Why?
|
Protein Prenylation | 1 | 2005 | 5 | 0.020 |
Why?
|
Heterocyclic Compounds | 1 | 2005 | 28 | 0.020 |
Why?
|
Oligonucleotides | 1 | 2005 | 80 | 0.020 |
Why?
|
Gadolinium | 1 | 2005 | 43 | 0.020 |
Why?
|
Organometallic Compounds | 1 | 2005 | 44 | 0.020 |
Why?
|
Erythroid-Specific DNA-Binding Factors | 1 | 2004 | 1 | 0.020 |
Why?
|
Helix-Loop-Helix Motifs | 1 | 2004 | 3 | 0.020 |
Why?
|
GATA1 Transcription Factor | 1 | 2004 | 7 | 0.020 |
Why?
|
K562 Cells | 1 | 2004 | 42 | 0.020 |
Why?
|
Carotid Stenosis | 1 | 2005 | 63 | 0.020 |
Why?
|
Antigens, CD34 | 1 | 2004 | 66 | 0.010 |
Why?
|
Cytochromes c | 1 | 2004 | 29 | 0.010 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2004 | 20 | 0.010 |
Why?
|
Glioma | 1 | 2005 | 79 | 0.010 |
Why?
|
Thiourea | 1 | 2004 | 9 | 0.010 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2004 | 40 | 0.010 |
Why?
|
Electrosurgery | 1 | 2004 | 7 | 0.010 |
Why?
|
Cyclooxygenase 2 | 1 | 2004 | 45 | 0.010 |
Why?
|
Phosphatidylserines | 1 | 2003 | 3 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2005 | 242 | 0.010 |
Why?
|
Mitogens | 1 | 2003 | 9 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2009 | 1816 | 0.010 |
Why?
|
Carbazoles | 1 | 2003 | 16 | 0.010 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2003 | 96 | 0.010 |
Why?
|
Polylysine | 1 | 2003 | 1 | 0.010 |
Why?
|
Adenoviruses, Human | 1 | 2003 | 3 | 0.010 |
Why?
|
Transduction, Genetic | 1 | 2003 | 45 | 0.010 |
Why?
|
eIF-2 Kinase | 1 | 2002 | 9 | 0.010 |
Why?
|
Sp1 Transcription Factor | 1 | 2002 | 21 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-abl | 1 | 2002 | 4 | 0.010 |
Why?
|
Biological Assay | 1 | 2003 | 45 | 0.010 |
Why?
|
Head and Neck Neoplasms | 2 | 1999 | 268 | 0.010 |
Why?
|
Europe | 1 | 2002 | 74 | 0.010 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2002 | 28 | 0.010 |
Why?
|
Sputum | 2 | 1993 | 65 | 0.010 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2003 | 60 | 0.010 |
Why?
|
Age of Onset | 1 | 2002 | 108 | 0.010 |
Why?
|
Age Distribution | 1 | 2002 | 168 | 0.010 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2002 | 137 | 0.010 |
Why?
|
Adolescent | 1 | 1993 | 6356 | 0.010 |
Why?
|
Activating Transcription Factor 2 | 1 | 2001 | 3 | 0.010 |
Why?
|
Hepatocytes | 1 | 2003 | 182 | 0.010 |
Why?
|
KB Cells | 1 | 2001 | 5 | 0.010 |
Why?
|
Epitopes | 1 | 1981 | 59 | 0.010 |
Why?
|
Skin | 2 | 1995 | 409 | 0.010 |
Why?
|
Distemper Virus, Canine | 1 | 1981 | 1 | 0.010 |
Why?
|
SSPE Virus | 1 | 1981 | 1 | 0.010 |
Why?
|
Immunologic Techniques | 1 | 1981 | 8 | 0.010 |
Why?
|
Hybrid Cells | 1 | 1981 | 6 | 0.010 |
Why?
|
Antibody Specificity | 1 | 1981 | 36 | 0.010 |
Why?
|
Mitotic Index | 1 | 2000 | 7 | 0.010 |
Why?
|
DNA, Antisense | 1 | 2000 | 2 | 0.010 |
Why?
|
Phosphoserine | 1 | 2000 | 6 | 0.010 |
Why?
|
Genes, cdc | 1 | 2000 | 6 | 0.010 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2000 | 47 | 0.010 |
Why?
|
Transcription Factor CHOP | 1 | 2000 | 7 | 0.010 |
Why?
|
Cell Size | 1 | 2000 | 45 | 0.010 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2000 | 29 | 0.010 |
Why?
|
Zinc Fingers | 1 | 2000 | 23 | 0.010 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2000 | 5 | 0.010 |
Why?
|
Hematoxylin | 1 | 2000 | 7 | 0.010 |
Why?
|
Ultrasonography, Doppler, Duplex | 1 | 2000 | 21 | 0.010 |
Why?
|
Sarcoma, Ewing | 1 | 2000 | 27 | 0.010 |
Why?
|
Renal Artery | 1 | 2000 | 33 | 0.010 |
Why?
|
Suction | 1 | 2000 | 23 | 0.010 |
Why?
|
Genetic Variation | 1 | 1981 | 213 | 0.010 |
Why?
|
Aorta, Abdominal | 1 | 2000 | 41 | 0.010 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2000 | 11 | 0.010 |
Why?
|
Genes, Viral | 1 | 1980 | 37 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2000 | 194 | 0.010 |
Why?
|
Cyclin-Dependent Kinase 2 | 1 | 2000 | 16 | 0.010 |
Why?
|
Angiography | 1 | 2000 | 126 | 0.010 |
Why?
|
Spleen | 1 | 1981 | 172 | 0.010 |
Why?
|
Mice, Mutant Strains | 1 | 2000 | 71 | 0.010 |
Why?
|
Stroke | 1 | 2005 | 492 | 0.010 |
Why?
|
Arteries | 1 | 2000 | 93 | 0.010 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2000 | 114 | 0.010 |
Why?
|
Immune Tolerance | 1 | 2000 | 96 | 0.010 |
Why?
|
Umbilical Veins | 1 | 1999 | 23 | 0.010 |
Why?
|
Carcinoma in Situ | 1 | 2000 | 73 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2000 | 280 | 0.010 |
Why?
|
Cysteine Proteinase Inhibitors | 1 | 1999 | 22 | 0.010 |
Why?
|
Registries | 1 | 2002 | 522 | 0.010 |
Why?
|
Tetracycline | 1 | 1999 | 20 | 0.010 |
Why?
|
Cytomegalovirus | 1 | 1999 | 27 | 0.010 |
Why?
|
Prevalence | 1 | 2002 | 944 | 0.010 |
Why?
|
Acute Disease | 1 | 2000 | 366 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 2000 | 192 | 0.010 |
Why?
|
Consensus Sequence | 1 | 1998 | 24 | 0.010 |
Why?
|
G-Box Binding Factors | 1 | 1998 | 1 | 0.010 |
Why?
|
Stereoisomerism | 1 | 1998 | 104 | 0.010 |
Why?
|
Jurkat Cells | 1 | 1998 | 29 | 0.010 |
Why?
|
Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I | 1 | 1998 | 2 | 0.010 |
Why?
|
Glycogen Synthase Kinases | 1 | 1998 | 1 | 0.010 |
Why?
|
Leukemia | 1 | 1998 | 65 | 0.010 |
Why?
|
Hepatocyte Growth Factor | 1 | 1998 | 9 | 0.010 |
Why?
|
cdc42 GTP-Binding Protein | 1 | 1998 | 11 | 0.010 |
Why?
|
Receptors, Glucocorticoid | 1 | 1998 | 32 | 0.010 |
Why?
|
bcl-X Protein | 1 | 1998 | 50 | 0.010 |
Why?
|
Erythropoietin | 1 | 1998 | 51 | 0.010 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 1997 | 8 | 0.010 |
Why?
|
Radiation, Ionizing | 1 | 1998 | 100 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 1998 | 129 | 0.010 |
Why?
|
Radiation Dosage | 1 | 1998 | 157 | 0.010 |
Why?
|
Trans-Activators | 1 | 1998 | 134 | 0.010 |
Why?
|
Sequence Homology | 1 | 1997 | 20 | 0.010 |
Why?
|
Benzophenanthridines | 1 | 1996 | 2 | 0.010 |
Why?
|
HL-60 Cells | 1 | 1996 | 18 | 0.010 |
Why?
|
Cytotoxins | 1 | 1996 | 16 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinase 9 | 1 | 1996 | 2 | 0.010 |
Why?
|
Stimulation, Chemical | 1 | 1996 | 28 | 0.010 |
Why?
|
Alkaloids | 1 | 1996 | 32 | 0.010 |
Why?
|
Neurotransmitter Agents | 1 | 1996 | 34 | 0.010 |
Why?
|
Cattle | 1 | 1996 | 210 | 0.010 |
Why?
|
Ionomycin | 1 | 1995 | 4 | 0.010 |
Why?
|
Skin Physiological Phenomena | 1 | 1995 | 15 | 0.010 |
Why?
|
Mutagenesis | 1 | 1995 | 60 | 0.010 |
Why?
|
Saccharomyces cerevisiae | 1 | 1996 | 190 | 0.010 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 1994 | 40 | 0.010 |
Why?
|
Fluocinolone Acetonide | 1 | 1994 | 5 | 0.010 |
Why?
|
Immunophenotyping | 1 | 1993 | 109 | 0.010 |
Why?
|
Gastrins | 1 | 1993 | 6 | 0.010 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 1992 | 13 | 0.010 |
Why?
|
Friend murine leukemia virus | 1 | 1992 | 2 | 0.010 |
Why?
|
Isotretinoin | 1 | 1992 | 6 | 0.010 |
Why?
|
Neoplasms, Second Primary | 1 | 1992 | 78 | 0.010 |
Why?
|
Single-Strand Specific DNA and RNA Endonucleases | 1 | 1990 | 4 | 0.010 |
Why?
|
Hormones, Ectopic | 1 | 1990 | 2 | 0.010 |
Why?
|
Radioimmunoassay | 1 | 1990 | 44 | 0.010 |
Why?
|
Arginine Vasopressin | 1 | 1990 | 8 | 0.010 |
Why?
|
Hyponatremia | 1 | 1990 | 11 | 0.010 |
Why?
|
Ribonucleases | 1 | 1989 | 4 | 0.010 |
Why?
|
Carcinoid Tumor | 1 | 1989 | 14 | 0.010 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 1989 | 19 | 0.010 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 1989 | 38 | 0.010 |
Why?
|
Heterozygote | 1 | 1989 | 81 | 0.010 |
Why?
|
Molecular Weight | 1 | 1988 | 84 | 0.010 |
Why?
|
Half-Life | 1 | 1988 | 84 | 0.000 |
Why?
|
Multiple Myeloma | 1 | 1981 | 2929 | 0.000 |
Why?
|
Viral Interference | 1 | 1980 | 3 | 0.000 |
Why?
|
RNA, Viral | 1 | 1980 | 125 | 0.000 |
Why?
|